Cardio Diagnostics Holdings Inc. (CDIO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Reviewing ARCA biopharma (NASDAQ:ABIO) and Cardio Diagnostics (NASDAQ:CDIO)
Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and ARCA biopharma (NASDAQ:ABIO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Profitability This table compares Cardio Diagnostics and ARCA biopharma’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Cardio Diagnostics -34,911.87% -415.33% -216.10% ARCA biopharma N/A -16.08% -15.51% Analyst Ratings This is a summary of current ratings and target prices for Cardio Diagnostics and ARCA biopharma, as reported by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 0 0 2 0 3.00 ARCA biopharma 0 0 0 0 N/A Cardio Diagnostics presently has a consensus price target of $1.35, indicating a potential upside of 84.93%. Given Cardio Diagnostics’ higher probable upside, equities analysts clearly believe Cardio Diagnostics is more favorable than ARCA biopharma. Volatility & Risk Cardio Diagnostics has a beta of 5.3, meaning that its share price is 430% more volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Earnings & Valuation This table compares Cardio Diagnostics and ARCA biopharma’s revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardio Diagnostics $20,000.00 828.19 -$8.38 million N/A N/A ARCA biopharma N/A N/A -$5.34 million ($0.42) -7.93 ARCA biopharma has lower revenue, but higher earnings than Cardio Diagnostics. Institutional and Insider Ownership 8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 56.4% of ARCA biopharma shares are held by institutional investors. 30.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 30.9% of ARCA biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Summary ARCA biopharma beats Cardio Diagnostics on 6 of the 10 factors compared between the two stocks. About Cardio Diagnostics (Get Free Report) Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois. About ARCA biopharma (Get Free Report) ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Cardio Diagnostics Holdings Inc. (CDIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cardio Diagnostics Holdings Inc. ever had a stock split?
Cardio Diagnostics Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Meeshanthini V. Dogan CEO | NASDAQ (CM) Exchange | 14159C202 CUSIP |
| US Country | 13 Employees | - Last Dividend | 13 May 2025 Last Split | - IPO Date |
Overview
Cardio Diagnostics Holdings, Inc., established in 2017 and based in Chicago, Illinois, stands at the forefront of cardiovascular disease diagnostics by pioneering the development and commercialization of epigenetic-based clinical tests. This innovative approach represents a significant leap forward in the early detection and risk assessment of cardiovascular diseases, particularly coronary heart disease (CHD), by leveraging the potential of epigenetics combined with traditional clinical indicators.
Products and Services
The company's product lineup focuses on providing precise and actionable insights into cardiovascular health risks through advanced testing methods. These include:
- Epi+Gen CHD: This is a cutting-edge three-year symptomatic coronary heart disease (CHD) risk assessment test designed to predict CHD events, such as heart attacks. By integrating epigenetic markers with traditional risk factors, Epi+Gen CHD offers a comprehensive view of a patient's likelihood of developing CHD, thereby enabling early intervention strategies to prevent the onset of the disease.
- PrecisionCHD: A revolutionary integrated epigenetic-genetic blood test that facilitates the early detection of coronary heart disease. PrecisionCHD merges genetic data with epigenetic information to provide a nuanced assessment of CHD risk. This test is particularly valuable for identifying individuals at an increased risk of developing CHD before the manifestation of symptoms, thereby paving the way for preemptive therapeutic measures.
